Evidence mapPaperPMID 41694307Full record

ReviewFrontiers in cardiovascular medicine2026

Insulin resistance with associated hyperinsulinemia as a risk factor for the development and worsening of HFpEF.

Serafino Fazio, Guido Carlomagno

Abstract readReview
In one paragraph

Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Serafino FazioFederico II University School of Medicine, Naples, Italy.
Guido CarlomagnoMediterranea Cardiocentro, Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prevalence of insulin resistance (IR) with associated hyperinsulinemia (HI) is increasing worldwide, as is the prevalence of heart failure with preserved left ventricular ejection fraction (HFpEF). This narrative review aims to explore the epidemiological and pathophysiological relationship between IR/HI and HFpEF, the possible mechanisms by which IR/HI could underlie HFpEF development and worsening, and the actual and future therapeutic implications of this interplay. The prevalence of IR in patients with HF is not negligible, and we will go through the existing literature highlighting this epidemiological association and the longitudinal data supporting a causative link. We will give a brief overview of molecular and physiological mechanisms connecting IR and HFpEF, such as the alteration of vascular homeostasis resulting in endothelial dysfunction and arterial hypertension, myocardial and vascular wall cell growth resulting in microvascular and macrovascular alterations of coronary circulation, and concentric remodeling of the left ventricle resulting in increased stiffness and diastolic dysfunction. We will review the concept of "diabetic cardiomyopathy" as a study model of these correlations. Finally, we will go through existing antidiabetic drugs with a current or potential future role in the treatment of HFpEF and summarize evidence on lifestyle and rehabilitative interventions in the field. Many of the cardiovascular abnormalities caused by IR/HI may be a contributing factor to the development and worsening of HFpEF. Further research is warranted to explore whether early diagnosis and specific treatment of IR/HI in at-risk populations may prevent HFpEF or delay its progression.

Indexed as

cardiovascular diseaseconcentric remodeling of left ventriclediastolic heart failureheart failure with normal ejection fractionheart failure with preserved ejection fractionhyperinsulinemiainsulin resistancetype 2 diabetes mellitus

Identifiers

PMID41694307
PMCPMC12901440

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.